BioLife Solutions (NASDAQ:BLFS) Insider Sells $1,952,998.45 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Karen Foster sold 96,923 shares of the business’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $20.15, for a total value of $1,952,998.45. Following the sale, the insider owned 113,742 shares of the company’s stock, valued at $2,291,901.30. The trade was a 46.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

BioLife Solutions Stock Performance

NASDAQ BLFS opened at $19.01 on Thursday. The firm has a market capitalization of $918.18 million, a price-to-earnings ratio of -172.80 and a beta of 1.90. BioLife Solutions, Inc. has a one year low of $18.29 and a one year high of $29.62. The company’s 50 day moving average price is $23.04 and its 200 day moving average price is $24.94.

Institutional Investors Weigh In On BioLife Solutions

A number of large investors have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. increased its stake in BioLife Solutions by 27.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 5,180,824 shares of the medical equipment provider’s stock worth $125,273,000 after buying an additional 1,113,972 shares during the period. Invesco Ltd. grew its stake in shares of BioLife Solutions by 9.2% during the fourth quarter. Invesco Ltd. now owns 3,932,191 shares of the medical equipment provider’s stock valued at $95,080,000 after acquiring an additional 332,747 shares in the last quarter. XTX Topco Ltd grew its stake in shares of BioLife Solutions by 280.4% during the fourth quarter. XTX Topco Ltd now owns 36,262 shares of the medical equipment provider’s stock valued at $877,000 after acquiring an additional 26,729 shares in the last quarter. SummitTX Capital L.P. purchased a new stake in shares of BioLife Solutions during the fourth quarter worth about $1,747,000. Finally, Sandler Capital Management purchased a new stake in shares of BioLife Solutions during the fourth quarter worth about $765,000. 93.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on BLFS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, January 21st. Wall Street Zen raised BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Northland Securities set a $34.00 price objective on BioLife Solutions in a research note on Monday, January 5th. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of BioLife Solutions in a research report on Monday, December 29th. Finally, UBS Group reiterated a “buy” rating on shares of BioLife Solutions in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.00.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.